 Artist: Jack Johnson: mp3 download Genre(s): Rock: Pop-Rock Instrumental ROck: Alternative Rock Jack Johnson's discography:  Sing-A-Longs and Lullabies For The Film Curious George Year: 2006 Tracks: 14  Brushfire Fairytales Year: 2006 Tracks: 13  In Between Dreams Year: 2005 Tracks: 14  On and on Year: 2004 Tracks: 16  Thicker Than Water Year: 2003 Tracks: 14  KFOG private concert Year: 2002 Tracks: 18  Brushfire Fairytales Year: 2002 Tracks: 13  Live In Boulder Year: 2001 Tracks: 18  Rares Year: Tracks: 2 Before Jack Johnson perfected his tilt star shipway, he was a supporter surfer on the professional route, with a sponsorship with Quiksilver. It was a life that was second nature for the Hawaiian native, for he began chasing waves as a tot, and by the time he was 17, he was an outstanding jockstrap on the word of mouth. However, Johnson was likewise testing his other creative outlets -- one existence riffle and the other existence euphony. It was during his college geezerhood as a film pupil at University of California at Santa Barbara when Johnson began writing songs. He and old match Chris Malloy and Emmett Malloy produced a channel-surf celluloid documentary entitled Thicker Than Water, in turn over spotlighting Johnson as a gifted cinematographer as well as a burgeoning singer/songwriter. His peers in and around the channel-surf circumference praised his work, and Thicker Than Water received props in Surfer cartridge clip for Video of the Year during 2000. The followup channel-surf flicker The September Sessions likewise earned the Adobe Highlight Award at the ESPN Film Festival that same yr. Still, Johnson steered away from a efflorescence professional sports life history and stuck with music -- something that would shortly realise him additional honors. G. Love & Special Sauce quickly took card to Johnson's otiose blues stylings, which besides wrought family and hip-hop for a modern john Rock twist, and included Johnson on "Rodeo Clowns" from G. Love's 1999 tone ending Philadelphonic. Johnson's four-track demo besides caught the ears of Ben Harper's right-hand valet, J.P. Plunier. This was sure as shooting mind-blowing for Johnson, for Harper's college rock linchpin Fight for Your Mind was one of his favorites and remained an inspiration. Aside from Plunier's production work, Harper likewise added his lap covering brand guitar puzzle out on Johnson's stifling debut, Brushfire Fairytales (Enjoy Records), in winter 2001. Two co-headlining tours followed passim springtime and summertime 2002; Johnson's sophomore travail, On and On, appeared in May 2003. Stateside dates with Harper followed in June and July. A third album, In Between Dreams arrived in March 2005, narrowly wanting the summit of the Billboard album chart in the process. Johnson earned two Brit Awards for In Between Dreams: International Male Solo Artist and International Breakthrough Act. In February, Johnson issued the soundtrack Curious George. Nielsen SoundScan gross revenue topped at 163,000 copies in its start week of release, earning Johnson his first-ever number unrivaled record album on Billboard's Top 200 and Rock Albums charts. |
Monday, 25 August 2008
Mp3 music: Jack Johnson
Friday, 15 August 2008
Breast Cancer Researchers Find Potential In New Combination Of Existing Cheaper Drugs
�Scientists in the UK and Finland have ascertained that a new combination of the chemotherapy dose doxorubicin and the bone-protecting drug
zoledronic acid, both of which are substantially cheaper than herceptin, stopped-up breast malignant neoplastic disease tumors growing in mice. Experts suggest that since both drugs are
already in manipulation, and if the combination proves effective and safe in human clinical trials, it should not subscribe to as long for it to be available as a modern treatment for patients.
The survey, which was funded by the Breast Cancer Campaign, was the work of Dr Penelope Ottewell and Dr Ingunn Holen from Sheffield University's
School of Medicine and Biomedical Sciences, plus other colleagues at Sheffield University and as well at the University of Kuopio in Finland. It is published in the 11
August 2008 issue of the Journal of the National Cancer Institute, JCNI.
Breast malignant neoplastic disease is ordinarily treated with a combination of drugs including chemotherapy to period tumors growing, and in cases of advanced cancer,
patients occupy a bisphosphonate to stopover bone red ink and protect against pain in the neck and weakness.
In their background information the researchers said that "test tube" experiments had already shown zoledronic acid enhanced the antitumour effects
of chemotherapy drugs, so they decided to see what effect it would have in living mouse models, either on its have, together, or in chronological sequence with the
chemotherapy agent doxorubicin.
For the study, the researchers induced breast cancer tumors in mice by injecting them with human white meat cancer cells and and so after 7 days they
injected them every week for 6 weeks with either (1) saline, or (2) doxorubicin, or (3) zoledronic vitriolic, or (4) doxorubicin and zoledronic vitriolic, or (5)
zoledronic acidulous followed 24 hours later by doxorubicin, or (6) doxorubicin followed 24 hours later by zoledronic sulfurous. There were about 8 or 9 mice in
each handling group.
Ottewell, Holen and colleagues then assessed the effect of the various treatments on tumor growth victimisation a kitchen range of methods, including measuring
tumor volume and rate of programmed tumor cell death (programmed cell death). They as well assessed the effect on bone.
The results showed that:
Treatment with doxorubicin or zoledronic acid alone, or zoledronic acid followed by doxorubicin 24 hours later, did not significantly decrease
neoplasm volume compared with saline.
Treatment with doxorubicin plus zoledronic acid produced significantly littler final tumor volumes than doxorubicin alone, zoledronic solitary, or
zoledronic acid followed 24 hours later by doxorubicin.
However, treatment with doxorubicin followed 24 hours later with zoledronic acid, "about completely abolished tumor growth".
Tumors from mice treated with doxorubicin followed by zoledronic acid showed more evidence of apoptosis or programmed cell death (using
front of caspase-3-positive cells as a bar) than tumors from mice treated with saline, with zoledronic virulent alone, or with zoledronic acid
followed by doxorubicin.
The treatment induced increase in programmed cell death was mirrored by a step-down in the cancer overconfident marker Ki-67.
There was no evidence of bone disease in whatever of the treatment groups as measured by microcomputed tomography and analysis of bone
histology.
The authors complete that:
"Sequential treatment with Dox [doxorubicin] followed by Zol [zoledronic acidulent] elicited substantial antitumor effects in hypodermic breast tumors in
vivo, in the absence of bone disease."
The researchers suggested that if these results are replicated in mankind in clinical settings, it could dramatically improve survival rates for thousands
of women currently having breast cancer intervention in the UK solitary.
Holen, wHO led the project, aforesaid that:
"Our work - exploitation a model system - has shown that treatment with the chemotherapy agent doxorubicin followed by zoledronic acid kills breast
tumours."
Holen explained that the results suggested that patients "may welfare the most if these two drugs are disposed in this particular order", and the team is
looking onward to "the results of a large breast cancer trial after this year to confirm our findings. This method of treatment could and so quickly be
incorporated into clinical practice."
Chief Executive of Breast Cancer Campaign, Pamela Goldberg, said:
"The results of this study are very encouraging and could change the way white meat cancer patients are tempered. The good news is the deuce treatments
victimised in this study are relatively inexpensive and already used in the clinic. Therefore we should promptly see the benefits giving women the best
possible chance of beating breast cancer."
Breast genus Cancer is the most vulgar cancer in the UK, where around 46,000 new cases are diagnosed every year.
"Antitumor Effects of Doxorubicin Followed by Zoledronic Acid in a Mouse Model of Breast Cancer.",
Penelope D. Ottewell , Hannu M�nkk�nen , Mark Jones , Diane V. Lefley , Robert E. Coleman , and Ingunn Holen
Journal of the National Cancer Institute, Advance Access published on August 11, 2008.
DOI 10.1093/jnci/djn240.
Click here for Abstract.
Sources: JNCI abstract, Sheffield University.
Written by: Catharine Paddock, PhD
View drug information on Herceptin.
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
More information
zoledronic acid, both of which are substantially cheaper than herceptin, stopped-up breast malignant neoplastic disease tumors growing in mice. Experts suggest that since both drugs are
already in manipulation, and if the combination proves effective and safe in human clinical trials, it should not subscribe to as long for it to be available as a modern treatment for patients.
The survey, which was funded by the Breast Cancer Campaign, was the work of Dr Penelope Ottewell and Dr Ingunn Holen from Sheffield University's
School of Medicine and Biomedical Sciences, plus other colleagues at Sheffield University and as well at the University of Kuopio in Finland. It is published in the 11
August 2008 issue of the Journal of the National Cancer Institute, JCNI.
Breast malignant neoplastic disease is ordinarily treated with a combination of drugs including chemotherapy to period tumors growing, and in cases of advanced cancer,
patients occupy a bisphosphonate to stopover bone red ink and protect against pain in the neck and weakness.
In their background information the researchers said that "test tube" experiments had already shown zoledronic acid enhanced the antitumour effects
of chemotherapy drugs, so they decided to see what effect it would have in living mouse models, either on its have, together, or in chronological sequence with the
chemotherapy agent doxorubicin.
For the study, the researchers induced breast cancer tumors in mice by injecting them with human white meat cancer cells and and so after 7 days they
injected them every week for 6 weeks with either (1) saline, or (2) doxorubicin, or (3) zoledronic vitriolic, or (4) doxorubicin and zoledronic vitriolic, or (5)
zoledronic acidulous followed 24 hours later by doxorubicin, or (6) doxorubicin followed 24 hours later by zoledronic sulfurous. There were about 8 or 9 mice in
each handling group.
Ottewell, Holen and colleagues then assessed the effect of the various treatments on tumor growth victimisation a kitchen range of methods, including measuring
tumor volume and rate of programmed tumor cell death (programmed cell death). They as well assessed the effect on bone.
The results showed that:
Treatment with doxorubicin or zoledronic acid alone, or zoledronic acid followed by doxorubicin 24 hours later, did not significantly decrease
neoplasm volume compared with saline.
Treatment with doxorubicin plus zoledronic acid produced significantly littler final tumor volumes than doxorubicin alone, zoledronic solitary, or
zoledronic acid followed 24 hours later by doxorubicin.
However, treatment with doxorubicin followed 24 hours later with zoledronic acid, "about completely abolished tumor growth".
Tumors from mice treated with doxorubicin followed by zoledronic acid showed more evidence of apoptosis or programmed cell death (using
front of caspase-3-positive cells as a bar) than tumors from mice treated with saline, with zoledronic virulent alone, or with zoledronic acid
followed by doxorubicin.
The treatment induced increase in programmed cell death was mirrored by a step-down in the cancer overconfident marker Ki-67.
There was no evidence of bone disease in whatever of the treatment groups as measured by microcomputed tomography and analysis of bone
histology.
The authors complete that:
"Sequential treatment with Dox [doxorubicin] followed by Zol [zoledronic acidulent] elicited substantial antitumor effects in hypodermic breast tumors in
vivo, in the absence of bone disease."
The researchers suggested that if these results are replicated in mankind in clinical settings, it could dramatically improve survival rates for thousands
of women currently having breast cancer intervention in the UK solitary.
Holen, wHO led the project, aforesaid that:
"Our work - exploitation a model system - has shown that treatment with the chemotherapy agent doxorubicin followed by zoledronic acid kills breast
tumours."
Holen explained that the results suggested that patients "may welfare the most if these two drugs are disposed in this particular order", and the team is
looking onward to "the results of a large breast cancer trial after this year to confirm our findings. This method of treatment could and so quickly be
incorporated into clinical practice."
Chief Executive of Breast Cancer Campaign, Pamela Goldberg, said:
"The results of this study are very encouraging and could change the way white meat cancer patients are tempered. The good news is the deuce treatments
victimised in this study are relatively inexpensive and already used in the clinic. Therefore we should promptly see the benefits giving women the best
possible chance of beating breast cancer."
Breast genus Cancer is the most vulgar cancer in the UK, where around 46,000 new cases are diagnosed every year.
"Antitumor Effects of Doxorubicin Followed by Zoledronic Acid in a Mouse Model of Breast Cancer.",
Penelope D. Ottewell , Hannu M�nkk�nen , Mark Jones , Diane V. Lefley , Robert E. Coleman , and Ingunn Holen
Journal of the National Cancer Institute, Advance Access published on August 11, 2008.
DOI 10.1093/jnci/djn240.
Click here for Abstract.
Sources: JNCI abstract, Sheffield University.
Written by: Catharine Paddock, PhD
View drug information on Herceptin.
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
More information
Thursday, 7 August 2008
Anne Briggs
Artist: Anne Briggs
Genre(s):
Folk
Discography:
The Time Has Come
Year: 2001
Tracks: 13
In the annals of pop and tribe medicine, there are few sagas unknown than that of Anne Briggs. An awesomely talented isaac M. Singer of traditional English sept music music, possessing of as pure and breathtakingly beautiful a voice as matchless could hope to deliver, she was the single nigh important influence on a grouping of female British folksingers that includes Sandy Denny, Maddy Prior, June Tabor, and Linda Thompson. Even Norma Waterson, herself a enormously important number in the British tribe music revival meeting of the mid-'60s, admits to being influenced by Briggs' piffle, and notes that Anne Briggs singlehandedly changed the means that English women folksingers american ginseng. What makes this tarradiddle so odd is that Briggs' entire recorded turnout consists of about 30 songs. She stopped up tattle at the old age of 27, supposedly because she despised the sound of her recorded voice. As folk music music became electrified and more and more popular, and bands such as Fairport Convention and Pentangle were reinventing the British folk music custom, and more and more women (Arenaceous Denny, et al.) were babble in a style started by Briggs, her caption flourished, thus far she refused to spill the beans.
Briggs was born in Nottinghamshire in 1944 and began tattle tribe music spell still in her teens. Within a mates of days she was a unconstipated at local tribe clubs, getting her bad break as a resultant of the Centre 42 circuit of 1962. The Centre 42 circuit was an attack by musicians and other artists (backed and supported by trade unions) to deliver politically collectivist cultural activities to areas outside of London. Part of Centre 42's invoke was that in each city, local talent would hearing for a slot as a support act. It was hither that Briggs got her crack and was observed by British phratry caption Ewan MacColl. She was so good that MacColl positive her to leave school and conjoin the lie of the tour. While touring with Centre 42, Briggs began working with MacColl's friend and co-architect of the British phratry music revival, Bert Lloyd. Briggs considers him the to the highest degree significant influence on her exercise, and her debut EP, The Hazards of Love, had Lloyd's fingerprints all over it. But he was non a simple Svengali trying to take advantage of a teen folksinger; he treasured to give her the direction (as well as the songs) she needed to become a brobdingnagian talent. Lloyd was smart enough to understand that this was an extraordinary, once-in-a-lifetime type of isaac Bashevis Singer, and he treated her with kid gloves, acquiring her to loose (Briggs was notorious for her jumpiness) and serving her phonograph recording some marvelous music. But Briggs had a job with recording her singing -- she detested doing it and hated the way she sounded, so much so that she retired from music, iII years shy of 30, already touted as the sterling legend in English phratry music. Briggs still lives semi-reclusively in England and is still not recording or vocalizing in public, merely her influence remains potent. As guitar player Martin Carthy so capably arrange it: "She didn't mess about. There were no histrionics. There was no posing. There was no self-aware style. She sang fluidly, well, with howling passion."
Subscribe to:
Posts (Atom)